Exvade Bioscience

What Exvade Bioscience does

Exvade Bioscience is a clinical-stage medical device company developing the Tumor Monorail Device (TMD), a bio-inspired permanent catheter-and-reservoir implant designed to redirect migrating glioblastoma cells away from critical brain regions toward a controlled extra-cortical reservoir. This architecture enables two commercially distinct functions: on-demand, minimally invasive tumor tissue sampling without repeat craniotomies, and direct targeted drug delivery across the blood-brain barrier via convection-enhanced delivery. The device is currently under investigation in a First-in-Human Phase 1 clinical trial at Duke University's Preston Robert Tisch Brain Tumor Center, evaluating safety in adults with recurrent glioblastoma in combination with two investigational immunotherapies (D2C7-IT and 2141-V11). It received FDA Breakthrough Device Designation in 2024, the first bio-inspired implant so designated for brain tumors.

The company's technology originated from academic research at Georgia Tech and Duke University and is protected by an extensive patent portfolio (60+ issued USPTO patents associated with the lead engineer alone). Its core customer segments are three-sided: (1) recurrent glioblastoma patients and their caregivers, who gain access to real-time tissue and drug-delivery options; (2) pharmaceutical companies running GBM Phase 1-2 trials, who gain a longitudinal tissue-access channel for multi-omics analysis during drug development; and (3) biotech developers of new GBM therapies, who may collaborate for tissue access and resistance-mechanism monitoring. Revenue mechanics are not yet established but are described as likely combining one-time device sales, per-procedure fees, licensing/royalty arrangements, and professional services for trial sponsors.

Exvade is privately held, headquartered in Atlanta with clinical operations in Durham, NC, employs 1-10 people, and has been funded to date primarily by non-dilutive sources including the NIH, Ian's Friends Foundation, and the Marcus Foundation. The company has no disclosed venture funding round, no commercial revenue, no application or API layer, and no disclosed pricing. Its near-term strategic posture is to advance the FIH trial, build academic medical center and pharma/biotech partnership pipelines, and expand translational work into pediatric and veterinary oncology indications.

Name

Exvade Bioscience

Legal name

Exvade Bioscience

Website

https://exvadebio.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Exvade Bioscience is a clinical-stage medical device company developing the Tumor Monorail Device, a bio-inspired brain implant that redirects glioblastoma cells to a reservoir for real-time tissue sampling and targeted drug delivery. It serves recurrent GBM patients and pharma/biotech GBM therapy developers, and is currently in a First-in-Human trial at Duke.

Ownership category

akta.pro rank

Product category

Neuro-oncology Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts) (HLAHAEAD)

akta.pro secondary industry

Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

Keywords

• Brain tumor implant
• Glioblastoma treatment
• Neuro-oncology devices
• Bio-inspired implants
• Convection-enhanced delivery

Headquarters

HQ city

Atlanta

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Device Commercialization: Pre-revenue medical device company. Revenue model not yet established but likely to include one-time device sales and/or per-procedure fees for the Tumor Monorail Device
2. Pharmaceutical Partnership / Tissue Access Services: The company mentions interest from pharmaceutical companies conducting Phase 1 or 2 clinical studies who want tissue access during trials, suggesting potential partnership or service revenue
3. Biotech Collaboration: Revenue opportunities from biotech companies developing new therapies for GBM who may partner for tissue access and monitoring during drug development

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Exvade Bioscience develops the Tumor Monorail Device (TMD), a bio-inspired intracranial implant for the treatment of glioblastoma multiforme (GBM). The TMD combines a permanent catheter with reservoir system and convection-enhanced delivery (CED) to redirect migrating tumor cells along biomolecular gradients into a controlled access reservoir for repeated tissue sampling and localized therapy. The device has received FDA Breakthrough Device Designation and is currently in a Phase 1 clinical trial at Duke University.

Product overview

Exvade Bioscience offers a single flagship product: the Tumor Monorail Device (TMD), a bio-inspired implant for treating brain cancer. The device is the first-ever FDA Breakthrough Device designed to guide tumor cells away from critical brain regions toward a designated safe zone while enabling repeated, minimally invasive tumor tissue sampling through a permanently placed catheter system. The company is conducting a First-in-Human clinical trial at Duke University evaluating the TMD's safety and effectiveness in monitoring tumor status during treatment, with the device combining advanced tumor monitoring capabilities and enabling direct drug delivery to bypass the blood-brain barrier.

Differentiator

Problem solved

Functional benefit

Products and services

• Tumor Monorail Device (TMD)
• Phase 1 Clinical Trial for TMD

Quantifiable outcome

• Enables real-time tumor monitoring over time while on therapy, identifying efficacy or limitations of treatments while preventing trauma and costs of repeated brain surgery

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core, strategic and supporting.

• Duke University - Preston Robert Tisch Brain Tumor CentercoreStrategic or Co-development PartnerPrimary clinical trial partner conducting First-in-Human Phase 1 study of Tumor Monorail Device for recurrent glioblastoma. Dr. Annick Desjardins, neuro-oncologist and professor of neurosurgery/neurology at Duke, is quoted supporting the technology's ability to enable real-time tumor monitoring during treatment.
• Georgia TechcoreStrategic or Co-development PartnerExvade was born from pioneering research initiated at Georgia Tech. The company's foundational science for the Tumor Monorail originated from academic research at Georgia Tech.
• Kessel MedicalstrategicTechnology or IntegrationISO 13485:2016 certified medical device manufacturer based in Vero Beach, Florida. Jack Griffis serves as Chief Technology Officer. Supports design and manufacturing of the Tumor Monorail Device.
• Children's Healthcare of AtlantastrategicStrategic or Co-development PartnerPediatric healthcare partner contributing clinical insights. Dr. Barun Brahma (CMO) has expertise in treating complex neurological conditions in children, informing the device's clinical applications.
• University of Minnesota - Veterinary MedicinesupportingStrategic or Co-development PartnerVeterinary medicine research partnership supporting translational aspects of the Tumor Monorail technology development.
• Wilson SonsinisupportingImplementation/ SI/ Consulting PartnerLegal counsel and IP advisory services supporting Exvade's intellectual property strategy and regulatory navigation.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Market position

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Exvade Bioscience